Concepedia

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

Komal Jhaveri, Sarat Chandarlapaty, Diana Lake, Teresa Gilewski, Mark E. Robson, Shari Goldfarb, Pamela Drullinsky, Steven Sugarman, Carolyn Wasserheit-Leiblich, Julie Fasano,

Clinical Breast Cancer · 2014 · 102 citations · 24 references

DOI

Concepts

References

24

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Clinical Cancer Research · 2012 · 903 citations · Full text

, , +16

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Shanu Modi, Alison Stopeck, Hannah Linden et al. · Clinical Cancer Research · 2011 · 424 citations

, , +16

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Shanu Modi, Alison Stopeck, Michael S. Gordon et al. · Journal of Clinical Oncology · 2007 · 334 citations

, , +15

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Lecia V. Sequist, Scott Gettinger, Neil Senzer et al. · Journal of Clinical Oncology · 2010 · 331 citations

, , +16